ImmunoGen, Inc. Email Format
Pharmaceutical ManufacturingIllinois, United States51-200 Employees
ImmunoGen, founded in 1980 and based in North Chicago, Illinois, is a mid-sized biopharmaceutical company focused on developing antibody-drug conjugate therapies for cancer. It operates within the pharmaceutical manufacturing space, emphasizing targeted oncology treatments designed to direct cytotoxic agents to tumor cells while sparing healthy tissue. Since early 2024, ImmunoGen has been part of AbbVie, a global biopharmaceutical company. Recent activity includes the launch of a Phase 3 study in March 2024 to evaluate mirvetuximab soravtansine in combination with bevacizumab as maintenance therapy for FRα-high recurrent platinum-sensitive ovarian cancers that have not progressed after second-line platinum-based chemotherapy. The company traces its roots to pioneering antibody-drug conjugate technology, contributing to the development of this therapeutic approach.